MX348708B - Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato. - Google Patents

Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato.

Info

Publication number
MX348708B
MX348708B MX2013009528A MX2013009528A MX348708B MX 348708 B MX348708 B MX 348708B MX 2013009528 A MX2013009528 A MX 2013009528A MX 2013009528 A MX2013009528 A MX 2013009528A MX 348708 B MX348708 B MX 348708B
Authority
MX
Mexico
Prior art keywords
beta
methods
methylbutyrate
hydroxy
cognitive function
Prior art date
Application number
MX2013009528A
Other languages
English (en)
Other versions
MX2013009528A (es
Inventor
Maria Lopez Pedrosa Jose
Manzano Martin Manuel
Barranco Perez Alejandro
Ramirez Gonzalez Maria
Rueda Cabrera Ricardo
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2013009528A publication Critical patent/MX2013009528A/es
Publication of MX348708B publication Critical patent/MX348708B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a una composición que comprende beta-hidroxi-beta-mutilbutirato para usarse en mejorar la cognición en un adulto mayor. Una composición que comprende beta-hidroxi-beta-metilbutirato para usarse en el tratamiento de una enfermedad cognitiva asociada con una enfermedad neurodegenerativa en un adulto mayor. Una composición que comprende beta-hidroxi-beta-metilbutirato para usarse en mejorar la función cognitiva en un infante, niño o adolescente.
MX2013009528A 2011-02-17 2012-02-13 Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato. MX348708B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Publications (2)

Publication Number Publication Date
MX2013009528A MX2013009528A (es) 2013-10-01
MX348708B true MX348708B (es) 2017-06-26

Family

ID=45757211

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009528A MX348708B (es) 2011-02-17 2012-02-13 Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato.

Country Status (12)

Country Link
US (1) US9326956B2 (es)
EP (1) EP2675298A1 (es)
JP (2) JP6034309B2 (es)
CN (1) CN103347406B (es)
AR (1) AR085297A1 (es)
BR (1) BR112013020643A2 (es)
CA (1) CA2825734C (es)
MX (1) MX348708B (es)
PH (1) PH12013501671A1 (es)
SG (1) SG192813A1 (es)
TW (1) TWI565420B (es)
WO (1) WO2012112419A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182812A1 (en) 2010-01-29 2012-09-27 Abbott Lab Nutritional emulsions comprising calcium hmb
WO2011094548A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US9326956B2 (en) 2011-02-17 2016-05-03 Abbott Laboratories Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20150351438A1 (en) * 2013-01-29 2015-12-10 Otc Nutrition Llc Micronutrient Fortification Delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
US20160029683A1 (en) * 2013-03-15 2016-02-04 Abbott Laboratories Low calorie infant formula containing beta-hydroxy-beta-methylbutyric acid
WO2015148982A1 (en) 2014-03-27 2015-10-01 Winterfield Roland W Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
WO2017048708A1 (en) * 2015-09-16 2017-03-23 Abbott Laboratories Reduced fat, shelf stable liquid nutritional composition
BR112018009406A8 (pt) * 2015-11-10 2019-02-26 Metabolic Tech Inc ?composição de aditivo de ração, produto de ração, método para prevenir, eliminar e/ou reduzir crescimento microbiano, e, revestimento para um produto de ração animal?
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 ＨＭＢＣａ含有顆粒の製造方法、及びサプリメント

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) * 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
US20080317886A1 (en) * 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
WO2009116546A1 (ja) 2008-03-18 2009-09-24 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
DK2381784T3 (en) 2008-12-09 2018-10-22 Metabolic Tech Inc Nutritional intervention to improve muscle function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
CN103338658A (zh) 2010-12-22 2013-10-02 雅培制药有限公司 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品
EP2658535A1 (en) 2010-12-27 2013-11-06 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
US9326956B2 (en) 2011-02-17 2016-05-03 Abbott Laboratories Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
SG11201405905WA (en) 2012-03-19 2014-11-27 Abbott Lab Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
MX2015003498A (es) 2012-09-17 2015-06-04 Abbott Lab Composiciones que contienen acido beta-hidroxi-beta-metilbutirico y usos de las mismas.

Also Published As

Publication number Publication date
CN103347406B (zh) 2015-08-05
PH12013501671A1 (en) 2021-06-02
TWI565420B (zh) 2017-01-11
CA2825734A1 (en) 2012-08-23
AR085297A1 (es) 2013-09-18
TW201309212A (zh) 2013-03-01
US20140249223A1 (en) 2014-09-04
WO2012112419A8 (en) 2014-03-06
US9326956B2 (en) 2016-05-03
JP2017061483A (ja) 2017-03-30
CN103347406A (zh) 2013-10-09
SG192813A1 (en) 2013-09-30
BR112013020643A2 (pt) 2016-08-02
JP6340394B2 (ja) 2018-06-06
WO2012112419A1 (en) 2012-08-23
JP6034309B2 (ja) 2016-11-30
CA2825734C (en) 2016-05-17
JP2014506890A (ja) 2014-03-20
MX2013009528A (es) 2013-10-01
EP2675298A1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
PH12013501671A1 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
AU2018270408A1 (en) Methods of inhibiting aging and treating aging-related disorders
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
NZ708727A (en) Conjugate compounds
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
PH12013501490A1 (en) Methods for diagnosing and treating eye-length related disorders
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MY179105A (en) Methods of treating alzheimer's disease
MY203971A (en) Anti-lag-3 antibodies and compositions
HK1213291A1 (zh) 用於治療胱氨酸尿症的胱硫醚β合酶
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX2019000677A (es) Células miméticas de células b.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
IN2014CN04009A (es)
PH12017501979A1 (en) Pharmaceutical compound
WO2014135878A3 (en) Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency
AU2015362063A8 (en) Compositions and methods for neuronal differentiation of cells

Legal Events

Date Code Title Description
FG Grant or registration